Literature DB >> 30017992

Spinocerebellar ataxia 27 with a novel nonsense variant (Lys177X) in FGF14.

Shiroh Miura1, Kengo Kosaka2, Ryuta Fujioka3, Yusuke Uchiyama4, Tomofumi Shimojo2, Takuya Morikawa2, Azusa Irie5, Takayuki Taniwaki5, Hiroki Shibata2.   

Abstract

Spinocerebellar ataxia 27 (SCA27) is an autosomal dominant SCA caused by variants in the fibroblast growth factor 14 (FGF14) gene. We examined a Japanese SCA patient whose deceased father also suffered from SCA. The patient was a 63-year-old male. He graduated from junior high school but received no further education. The predominant complaint was slowly progressive dysarthria and gait disturbance, which appeared at age 47. He showed pathological saccadic dysmetria, saccadic intrusions into smooth pursuit eye movements, dysarthria, and limb and truncal ataxia. His gait was wide-based but he did not require a walking stick. Limb muscle strength was intact. Deep tendon reflexes were normal or slightly reduced. Pathological reflexes were absent. He demonstrated mildly impaired vibration sense in the lower limbs. There was no urinary dysfunction. Brain MRI showed cerebellar atrophy without brainstem involvement. We first confirmed the absence of repeat expansion in genes known to be responsible for SCAs 1-3, 6-8, 10, 12, 17, 36 and dentatorubral-pallidoluysian atrophy. By exome analysis, we identified a novel heterozygous variant (NM_004115, c.529A>T; Lys177X) in exon 4 of the FGF14 gene. This variant is expected to generate a truncated FGF14 protein lacking the heparin binding sites, those are likely to modify the activity of FGF14. We confirmed the absence of the variant in 502 healthy Japanese individuals by Sanger sequencing. There is no record of the variant in public databases. We conclude that the novel variation in FGF14 is causative for SCA27 in this patient.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Autosomal dominant; FGF14; Nonsense; Spinocerebellar ataxia 27 (SCA27)

Mesh:

Substances:

Year:  2018        PMID: 30017992     DOI: 10.1016/j.ejmg.2018.07.005

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

Review 1.  Paroxysmal Movement Disorders: Recent Advances.

Authors:  Zheyu Xu; Che-Kang Lim; Louis C S Tan; Eng-King Tan
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-11       Impact factor: 5.081

Review 2.  Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.

Authors:  Giacomo Garone; Alessandro Capuano; Lorena Travaglini; Federica Graziola; Fabrizia Stregapede; Ginevra Zanni; Federico Vigevano; Enrico Bertini; Francesco Nicita
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

3.  High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na+ channel complex.

Authors:  Paul A Wadsworth; Oluwarotimi Folorunso; Nghi Nguyen; Aditya K Singh; Daniela D'Amico; Reid T Powell; David Brunell; John Allen; Clifford Stephan; Fernanda Laezza
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

Review 4.  Spinocerebellar ataxias (SCAs) caused by common mutations.

Authors:  Ulrich Müller
Journal:  Neurogenetics       Date:  2021-08-16       Impact factor: 2.660

5.  Exploring the Genomic Patterns in Human and Mouse Cerebellums Via Single-Cell Sequencing and Machine Learning Method.

Authors:  ZhanDong Li; Deling Wang; HuiPing Liao; ShiQi Zhang; Wei Guo; Lei Chen; Lin Lu; Tao Huang; Yu-Dong Cai
Journal:  Front Genet       Date:  2022-03-04       Impact factor: 4.599

6.  Pharmacologically Targeting the Fibroblast Growth Factor 14 Interaction Site on the Voltage-Gated Na+ Channel 1.6 Enables Isoform-Selective Modulation.

Authors:  Nolan M Dvorak; Cynthia M Tapia; Aditya K Singh; Timothy J Baumgartner; Pingyuan Wang; Haiying Chen; Paul A Wadsworth; Jia Zhou; Fernanda Laezza
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.